



THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

RAINBOW CHILDREN'S MEDICARE LIMITED

Our Company was originally incorporated as 'Rainbow Children's Medicare Private Limited' under the provisions of the Companies Act, 1956, as a private limited company, at Hyderabad, Telangana, pursuant to a certificate of incorporation dated August 7, 1996, issued by the Registrar of Companies, Hyderabad at Telangana ("RoC"). Subsequently, our Company was converted into a public limited company, and the name of our Company was changed to 'Rainbow Children's Medicare Limited' pursuant to a special resolution passed by the Shareholders of our Company on November 3, 2021 and a fresh certificate of incorporation was consequently issued by the RoC on November 20, 2021 under the Companies Act, 2013. For further details in relation to the changes to the name of our Company and the Registered Office, see "History and Certain Corporate Matters" on page 294 of the red herring prospectus of the Company dated April 19, 2022 ("RHP").

Registered Office: 8-2-120/103/1, Survey No. 403, Road No. 2, Banjara Hills, Hyderabad - 500 034, Telangana. Telephone: + 91 40 49692244
Corporate Office: 8-2-19/1/A, Daulet Arcade, Road No. 11, Banjara Hills, Hyderabad - 500 034, Telangana, Telephone: +91 40 49692244; Contact Person: Ashish Kapil, Company Secretary and Compliance Officer
E-mail: companysecretary@rainbowhospitals.in; Website: www.rainbowhospitals.in; Corporate Identity Number: U85110TG1998PLC029914

OUR PROMOTERS: DR. RAMESH KANCHARLA, DR. DINESH KUMAR CHIRLA AND DR. ADARSH KANCHARLA

INITIAL PUBLIC OFFERING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹10 EACH ("EQUITY SHARES") OF RAINBOW CHILDREN'S MEDICARE LIMITED (THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ [●] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [●] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹ [●] MILLION (THE "OFFER"), COMPRISING A FRESH ISSUE OF UP TO [●] EQUITY SHARES AGGREGATING UP TO ₹ 2,800.00 MILLION (THE "FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 24,000,900 EQUITY SHARES AGGREGATING UP TO ₹ [●] MILLION BY THE SELLING SHAREHOLDERS REFERRED TO IN ANNEXURE TO THE RHP (THE "OFFER FOR SALE") ON PAGE NUMBER 641 OF THE RHP. THE OFFER INCLUDES A RESERVATION OF UP TO 300,000 EQUITY SHARES AGGREGATING UP TO [●] MILLION (CONSTITUTING UP TO [●] % OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL) FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HERINAFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER WOULD CONSTITUTE [●] % AND [●] %, RESPECTIVELY, OF OUR POST-OFFER PAID-UP EQUITY SHARE CAPITAL.

QIB Portion: Not more than 50% of the Net Offer
Non-Institutional Portion: Not less than 15% of the Net Offer
Retail Portion: Not less than 35% of the Net Offer
(Retail Individual Bidders are those who have Bid for the Equity Shares for an amount not more than ₹ 200,000 in the Offer)
Employee Reservation Portion: Up to 300,000 Equity Shares aggregating up to ₹ [●] million

PRICE BAND: ₹516 TO ₹542 PER EQUITY SHARE OF FACE VALUE OF ₹10 EACH.
THE FLOOR PRICE IS 51.60 TIMES THE FACE VALUE OF THE EQUITY SHARES AND THE CAP PRICE IS 54.20 TIMES THE FACE VALUE OF THE EQUITY SHARES.
BIDS CAN BE MADE FOR A MINIMUM OF 27 EQUITY SHARES AND IN MULTIPLES OF 27 EQUITY SHARES THEREAFTER.
A DISCOUNT OF ₹ 20 PER EQUITY SHARE IS BEING OFFERED TO ELIGIBLE EMPLOYEES BIDDING IN THE EMPLOYEE RESERVATION PORTION.

Risks to Investors

- The Offer Price at upper end of the price band is ₹ 542 per Equity Share. However, the average cost of acquisition per Equity Share for the Selling Shareholders is as follows:

Name of the Selling shareholder	Avg. cost of acquisition per Equity Share as on the date of the RHP (in ₹)	Name of the Selling shareholder	Avg. cost of acquisition per Equity Share as on the date of the RHP (in ₹)
Dr. Ramesh Kancharla (Promoter Selling Shareholder)	7.32	Mrs. Padma Kancharla (Other Selling Shareholder)	Nil
Dr. Dinesh Kumar Chirla (Promoter Selling Shareholder)	0.91	British International Investment plc (formerly known as CDC Group plc) (Investor Selling Shareholder)	54.50
Dr. Adarsh Kancharla (Promoter Selling Shareholder)	Nil	CDC India (Investor Selling Shareholder)	110.29

- Our revenues are highly dependent on our hospitals in Hyderabad and Bengaluru. Of our 14 hospitals, six are situated in Hyderabad, Telangana and three are situated in Bengaluru, Karnataka. Any impact on the revenues from these hospitals could materially affect our business, financial condition and results of operations. The proportion of volumes at hospitals in Hyderabad and Bengaluru, of our aggregate inpatient and outpatient volumes across all our hospitals are as follows:

Particulars	Fiscal 2019	Fiscal 2020	Fiscal 2021	For the nine months period ended December 31, 2021
Proportion of volumes at hospitals in Hyderabad and Bengaluru to aggregate inpatient and outpatient volumes across all our hospitals	84.07%	81.89%	78.98%	77.28%

- We are dependent on our medical professionals and our business and financial results could be impacted if we are not able to attract and retain such medical professionals. The attrition rate for our permanent employees, which includes nurses (including interns and paramedical personnel) are as follows:

Particulars	Fiscal 2019	Fiscal 2020	Fiscal 2021	For the nine months period ended December 31, 2021
Attrition rate for our permanent employees, which includes nurses (including interns and paramedical personnel)	35.41%	38.75%	45.50%	26.74%

- The Offer Price, market capitalization to revenue multiple and price to earnings ratio based on the Offer Price of our Company, may not be indicative of the market price of our Company on listing or thereafter. The details of our price earnings ratio and market capitalization to revenue from operations based on the upper end of the price band i.e. ₹ 542 per Equity Share are given below:

Particulars	Price to earnings ratio (based on diluted EPS)	Market capitalization to revenue
For the year ended March 31, 2021	127.53	7.91

For details of market capitalization to revenue multiple for our listed peers that have a similar business profile to us, please see "Basis for Offer Price" section at page 171 of the RHP.

- Weighted average cost of acquisition of all shares transacted in last three years and one year preceding the date of the Red Herring Prospectus ("RHP")

Period	Weighted Average Cost of Acquisition [^] (in ₹)	Cap Price (₹ 542) is 'X' times the Weighted Average Cost of Acquisition	Range of acquisition price: Lowest Price - Highest Price [^] (in ₹)
Last 1 year	7.80	69.49	0-70
Last 3 years	7.80	69.49	0-70

[^]As certified by Madhu Mantri and Associates, Chartered Accountants, in their certificate dated April 19, 2022

- We are significantly dependent on certain specialties for a majority of our revenues. We have four core specialties, namely secondary pediatric care, tertiary pediatric care, quaternary pediatric care and women care (gynecology, obstetrics and related services), of which our secondary pediatric care services have historically accounted for the largest portion of our revenues. See "Our Business - Key Specialties - Pediatric services (including secondary, tertiary and quaternary care)" on page 259 of the RHP.

BID/OFFER PROGRAMME

BID/OFFER OPEN

BID/OFFER CLOSES ON : FRIDAY, APRIL 29, 2022[#]

[#]UPI Mandate end time and date shall be at 12:00 pm on May 2, 2022.

In case of any revision to the Price Band, the Bid/Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid/Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company, Dr. Ramesh Kancharla (acting on behalf of the other Promoter Selling Shareholders and the Other Selling Shareholder) and the Investor Selling Shareholders may, in consultation with the BRLMs, for reasons to be recorded in writing, extend the Bid / Offer Period for a minimum of three Working Days, subject to the Bid / Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/Offer Period, if applicable, will be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the BRLMs and at the terminals of the Syndicate Member(s) and by intimation to the Designated Intermediaries and the Sponsor Banks, as applicable.

The Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the SCRR, read with Regulation 31 of the SEBI ICDR Regulations, and in compliance with Regulation 6(1) of the SEBI ICDR Regulations, wherein not more than 50% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs"), and such portion, the "QIB Portion", provided that our Company, Dr. Ramesh Kancharla (acting on behalf of the other Promoter Selling Shareholders and the Other Selling Shareholder) and the Investor Selling Shareholders has, in consultation with the BRLMs, allocated up to 60% of the QIB Portion to Anchor Investors on a discretionary basis (the "Anchor Investor Portion"), of which one-third was reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price, in accordance with the SEBI ICDR Regulations. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from the Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Offer shall be available for allocation to Non-Institutional Bidders ("Non-Institutional Portion") of which one-third of the Non-Institutional Portion shall be available for allocation to Bidders with an application size of more than ₹ 200,000 and up to ₹ 1,000,000 and two-thirds of the Non-Institutional Portion shall be available for allocation to Bidders with an application size of more than ₹ 1,000,000 and under-subscription in either of these two sub-categories of Non-Institutional Portion may be allocated to Bidders in the other sub-category of Non-Institutional Portion, and not less than 35% of the Net Offer shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. All potential Bidders, other than Anchor Investors, are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA accounts and UPI ID (in case of Retail Individual Bidders using UPI Mechanism), if applicable, in which the corresponding Bid Amounts will be blocked by the self-certified syndicate banks ("SCSBs") or under the UPI Mechanism, as applicable, to participate in the Offer. Anchor Investors are not permitted to participate in the Anchor Investor Portion through the ASBA process. See "Offer Procedure" on page 523 of the RHP.

Bidders/Applicants should ensure that DP ID, PAN, Client ID and UPI ID (for RIBs bidding through the UPI mechanism) are correctly filled in the Bid cum Application Form. The DP ID, PAN and Client ID provided in the Bid cum Application Form should match with the DP ID, PAN, Client ID available in the Depository database, otherwise, the Bid cum Application Form is liable to be rejected. Bidders/Applicants should ensure that the beneficiary account provided in the Bid cum Application Form is active. Bidders/Applicants should note that on the basis of the PAN, DP ID, Client ID and UPI ID (for RIBs bidding through the UPI mechanism) as provided in the Bid cum Application Form, the Bidder/Applicant may be deemed to have authorised the Depositories to provide to the Registrar to the Offer, any requested Demographic Details of the Bidder/Applicant as available on the records of the depositories. These Demographic Details may be used, among other things, for giving Allotment Advice or unblocking of ASBA Account or for other correspondence(s) related to the Offer. Bidders/Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from failure to update the Demographic Details would be at the Bidders/Applicants' sole risk. Investors must ensure that their PAN is linked with Aadhaar and are in compliance with CBDT notification dated Feb 13, 2020 and press release dated June 25, 2021.

Contents of the Memorandum of Association of the Company as regards its objects: For information on the main objects of the Company, please see the section "History and Certain Corporate Matters" beginning on page 294 of the RHP. The Memorandum of Association of the Company is a material document for inspection in relation to the Offer. For further details, please see the section entitled "Material Contracts and Documents for Inspection" beginning on page 625 of the RHP.

Liability of the members of the Company: Limited by shares

Amount of share capital of the Company and Capital Structure: The authorised, issued, subscribed and paid-up share capital of the Company as on the date of the RHP is as follows: The authorised share capital of the Company is ₹ 1,390,556,160 divided into 139,055,616 Equity Shares of face value of ₹ 10 each, ₹ 55,045,008 divided into 1,146,771 Series A 0.0001% Compulsorily Convertible Preference Shares ("Series A CCPS") of face value of ₹ 48 each and ₹ 54,398,832 divided into 1,133,309 Series B 0.0001% Compulsorily Convertible Preference Shares ("Series B CCPS") of face value of ₹ 48 each. The issued, subscribed and paid-up share capital of the Company is ₹ 963,340,080 divided into 96,334,008 Equity Shares of face value of ₹ 10 each. For details, please see the section entitled "Capital Structure" on page 112 of the RHP.

Names of signatories to the Memorandum of Association of the Company and the number of Equity Shares subscribed by them: The names of the signatories of the Memorandum of Association of our Company are Dr. Ramesh Kancharla, Dr. Prasad S.V. Vankayalapati and Mr. D. Suresh. For details of the share capital history and capital structure of our Company, please see the section entitled "Capital Structure" on page 112 of the RHP.

Listing: The Equity Shares offered through the Red Herring Prospectus are proposed to be listed on the Stock Exchanges. Our Company has received 'in-principle' approvals from BSE and NSE for the listing of the Equity Shares pursuant to letters each dated January 19, 2022. For the purposes of the Offer, the Designated Stock Exchange shall be NSE. A signed copy of each of the Red Herring Prospectus has been and of the Prospectus shall be, filed with the RoC in accordance with the Companies Act, 2013. For further details of the material contracts and documents available for inspection from the date of the Red Herring Prospectus until the Bid / Offer Closing Date, see "Material Contracts and Documents for Inspection" on page 625 of the RHP.

Disclaimer Clause of the Securities and Exchange Board of India ("SEBI"): SEBI only gives its observations on the offer documents and this does not constitute approval of either the Offer or the specified securities or the offer document. The investors are advised to refer to page 491 of the RHP for the full text of the disclaimer clause of SEBI.

Disclaimer Clause of BSE: It is to be distinctly understood that the permission given by BSE should not in any way be deemed or construed that the RHP has been cleared or approved by BSE nor does it certify the correctness or completeness of any of the contents of the RHP. The investors are advised to refer to page 494 of the RHP for the full text of the disclaimer clause of BSE.

Disclaimer Clause of NSE (Designated Stock Exchange): It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Offer Document has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Offer Document. The investors are advised to refer to page 494 of the RHP for the full text of the disclaimer clause of NSE.

General Risk: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have not been recommended or approved by the SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Red Herring Prospectus. Specific attention of the investors is invited to "Risk Factors" on page 47 of the RHP.

THE EQUITY SHARES OF OUR COMPANY WILL GET LISTED ON MAIN BOARD PLATFORM OF BSE AND NSE

<p>Simple, Safe, Smart way of Application!!! # Applications supported by blocked amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account. For further details, check section on ASBA below. Mandatory in public issues. No cheque will be accepted.</p>	<p>UPI Now available in ASBA for Retail Individual Investors ("RIIs") applying through Registered Brokers, DPs and RTAs. RIIs also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account. Investors are required to ensure that the bank account used for bidding is linked to their PAN. Bidders must ensure that their PAN is linked with Aadhaar and are in compliance with CBDT notification dated February 13, 2020 and press release dated June 25, 2021</p>
<p>ASBA has to be availed by all the investors except anchor investors. UPI may be availed by Retail Individual Bidders. For details on the ASBA and UPI process, please refer to the details given in ASBA form and abridged prospectus and also please refer to the section "Offer Procedure" on page 523 of the RHP. The process is also available on the website of Association of Investment Bankers of India ("AIB") and Stock Exchanges and in the General Information Document. ASBA bid-cum-application forms can be downloaded from the websites of BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE"), and together with BSE, the "Stock Exchanges" and can be obtained from the list of banks that is displayed on the website of SEBI at www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFPI=yes&intmid=35 and www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFPI=yes&intmid=43, respectively as updated from time to time. For the list of UPI apps and banks live on IPO, please refer to the link: www.sebi.gov.in. RIIs Bidding using the UPI mechanism may apply through the SCSBs and mobile applications whose names appear on the website of SEBI, as updated from time to time. HDFC Bank Limited, ICICI Bank Limited, Axis Bank Limited and Kotak Mahindra Bank Limited has been appointed as Sponsor Banks for the Offer, in accordance with the requirements of the SEBI Circular dated November 1, 2018 as amended. For offer related queries, please contact the BRLMs on their respective email IDs as mentioned below. For UPI related queries, investors can contact NPCI at the toll free number: 18001201740 and mail id: ipo.uipi@npci.org.in.</p>	

BOOK RUNNING LEAD MANAGERS

REGISTRAR TO THE OFFER

COMPANY SECRETARY AND COMPLIANCE OFFICER

Kotak Investment Banking	J.P.Morgan	IIFL SECURITIES	KFINTECH
<p>Kotak Mahindra Capital Company Limited 27 BKC, 1st Floor, Plot No. C-27, 'G' Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. Telephone: +91 (22) 4336 0000 E-mail: rainbow.ipo@kotak.com Website: https://investmentbank.kotak.com Investor Grievance ID: kmcredressa@kotak.com Contact Person: Ganesh Rane SEBI Registration Number: INM000008704</p>	<p>J.P. Morgan India Private Limited J.P. Morgan Towers, Off CST Road, Kalina, Santacruz East, Mumbai - 400 098, Maharashtra, India. Telephone: +91 (22) 6157 3000 E-mail: RAINBOW_IPO@jpmorgan.com Website: www.jpmpl.com Investor Grievance ID: investorsmb.jpmpl@jpmorgan.com Contact Person: Krishna S Gohil SEBI Registration Number: INM000002970</p>	<p>IIFL Securities Limited 10th Floor, IIFL Centre, Kamala City, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India. Telephone: +91 (22) 4646 4728 E-mail: rainbow.ipo@iiflcap.com Website: www.iiflcap.com Investor Grievance ID: ig.ib@iiflcap.com Contact Person: Shrish Chikalge / Dhruv Bhagwat SEBI Registration Number: INM00010940</p>	<p>KFin Technologies Limited (formerly known as Kfin Technologies Private Limited) Selenium, Tower-B, Plot 31 and 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddy - 500 032 Telangana, India. Telephone: +91 40 6716 2222 E-mail: rcml ipo@kfintech.com Website: www.kfintech.com Investor Grievance ID: enward.ris@kfintech.com Contact Person: M Murali Krishna SEBI Registration Number: INR00000221</p>

AVAILABILITY OF THE RHP: Investors are advised to refer to the RHP and the "Risk Factors" on page 47 of the RHP, before applying in the Offer. A copy of the RHP shall be available on website of SEBI at www.sebi.gov.in and is available on the websites of the BRLMs, i.e. Kotak Mahindra Capital Company Limited, J.P. Morgan India Private Limited and IIFL Securities Limited at <https://investmentbank.kotak.com>, www.jpmpl.com and www.iiflcap.com, respectively and on the websites of BSE and NSE at www.bseindia.com and www.nseindia.com, respectively.

AVAILABILITY OF BID CUM APPLICATION FORMS: Bid cum Application Forms can be obtained from the registered office of Rainbow Children's Medicare Limited, Telephone: +91 40 49692244; BRLMs: Kotak Mahindra Capital Company Limited, Telephone: +91 (22) 4336 0000, J.P. Morgan India Private Limited, Telephone: +91 (22) 6157 3000 and IIFL Securities Limited, Telephone: +91 (22) 4646 4728 and Syndicate Member: Kotak Securities Limited, Telephone: +91 (22) 6218 5470 at the select locations of the Sub-syndicate Members (as given below), SCSBs, Registered Brokers, RTAs and CDPs participating in the Offer. ASBA Forms will also be available on the websites of BSE and NSE and the Designated Branches of SCSBs, the list of which is available at websites of the Stock Exchanges and SEBI.

Sub-Syndicate Members: Almondz Global Securities Ltd, Anand Rathi Share & Stock Brokers Ltd., Axis Capital Limited, Bajaj Financial Securities Limited, Centrum Broking Limited, Dalal & Broacha Stock Broking Private Limited, Edelweiss Broking Limited, ICICI Securities Limited, IDBI Capital Markets & Securities Limited, JM Financial Services Limited, Jobanputra Fiscal Services Private Limited, Kantilal Chhaganlal Sec Pvt Ltd, Keynote Capitals Limited, KJM Capital Market Securities Limited, LKP Securities Limited, Motilal Oswal Financial Services Ltd, Nirmla Bang Securities Pvt. Ltd., Prabhudas Lalladher Pvt Ltd, Pravin Ratilal Share & Stock Brokers Limited, RR Equity Brokers Private Limited, SBICap Securities Limited, Sharekhan Ltd, SMC Global Securities Ltd and YES Securities (India) Limited

Escrow Collection Bank, Public Offer Bank and Refund Bank: HDFC Bank Limited

Sponsor Banks: HDFC Bank Limited, ICICI Bank Limited, Axis Bank Limited and Kotak Mahindra Bank Limited

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the RHP.

For RAINBOW CHILDREN'S MEDICARE LIMITED
On behalf of the Board of Directors
Ashish Kapil
Company Secretary and Compliance Officer

Place: Hyderabad, Telangana
Date: April 27, 2022

RAINBOW CHILDREN'S MEDICARE LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the RHP with RoC on Tuesday, April 19, 2022. The RHP is available on the website of SEBI at www.sebi.gov.in, websites of BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com, respectively and is available on the websites of the BRLMs, i.e. Kotak Mahindra Capital Company Limited, J.P. Morgan India Private Limited and IIFL Securities Limited at <https://investmentbank.kotak.com>, www.jpmpl.com and www.iiflcap.com, respectively. Investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, refer to the Red Herring Prospectus, including the section titled "Risk Factors" of the Red Herring Prospectus. Specific attention of the investors is invited to "Risk Factors" beginning on page 47 of the RHP.

The Equity Shares offered in the Offer have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any other applicable law of the United States and, unless so registered, may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (a) in the United States only to persons reasonably believed to be "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act) pursuant to Section 4(a) of the U.S. Securities Act and (b) outside of the United States in offshore transactions as defined in and in compliance with Regulation S and the applicable laws of the jurisdiction where those offers and sales are made. There will be no public offering of the Equity Shares in the United States.